Opening plenary Chair: Andrew Morris, Director, Health Data - - PowerPoint PPT Presentation

▶
opening plenary
SMART_READER_LITE
LIVE PREVIEW

Opening plenary Chair: Andrew Morris, Director, Health Data - - PowerPoint PPT Presentation

Oct 25, 2023 318 likes •920 views

Opening plenary Chair: Andrew Morris, Director, Health Data Research UK Welcome address: Patrick Vallance, Government Chief Scientific Adviser and Co-Chair, Scientific Advisory Committee for Emergencies (SAGE) This session will

slide-1
SLIDE 1

Opening plenary

  • Chair:
  • Andrew Morris, Director, Health Data Research UK
  • Welcome address:
  • Patrick Vallance, Government Chief Scientific Adviser and Co-Chair,

Scientific Advisory Committee for Emergencies (SAGE)

This session will start at 09:30BST. Please use the Q&A function to ask questions to speakers. You are welcome to comment using the chat function, but we cannot guarantee this will be monitored.

slide-2
SLIDE 2

How UK health data research has pivoted for COVID-19

  • Andrew Morris, Director, Health Data Research UK
  • Caroline Cake, Chief Executive Officer, Health Data Research UK
slide-3
SLIDE 3

HDR UK’s mission is to unite the UK’s health data to enable discoveries that improve people’s lives Our 20-year vision is for large scale data and advanced analytics to benefit every patient interaction, clinical trial, biomedical discovery and enhance public health.

| 4

slide-4
SLIDE 4

To achieve this our strategy focuses on uniting, improving and using health data….

| 5

slide-5
SLIDE 5

…delivering through the Gateway, Alliance and Hubs…

slide-6
SLIDE 6

…and through 6 national research priority areas

| 7

slide-7
SLIDE 7

….and the institute is continuing to evolve to deliver this strategy

| 8

2017 2018 2019

INCEPTION

  • 10 funders

SUBSTANTIVE SITES

  • 6 Research sites with

20 research organisations GROWTH

  • >20 Alliance members
  • 8 hubs with > 100 partners
  • 11 Sprints
  • 10 training sites
  • Public Advisory Group

10 FUNDERS 10 FUNDERS 6 RESEARCH SITES 20 RESEARCH ORGANISATIONS 6 RESEARCH SITES 8 HUBS >20 ALLIANCE MEMBERS PUBLIC ADVISORY GROUP 10 FUNDERS 78 RESEARCH ORGANISATIONS 10 TRAINING SITES 100 ORGANISATIONS 11 SPRINTS

2020

GROWTH

  • 30 Alliance members
  • 8 Research sites
  • 78 research organisations
  • 4 Catalyst projects
  • 60 patients on COVID group

8 RESEARCH SITES 8 HUBS >30 ALLIANCE MEMBERS PUBLIC ADVISORY GROUP 12 FUNDERS 78 RESEARCH ORGANISATIONS 10 TRAINING SITES 100 ORGANISATIONS 60 COVID patient advisors

slide-8
SLIDE 8

We are now an institute made up of 86 organisations in 56 offices across 32 locations

| 9 HEALTH DATA RESEARCH HUBS BREATHE DATA-CAN Discover-NOW Gut Reaction INSIGHT PIONEER NHS DigiTrials BHF Data Science Centre TRAINING LOCATIONS (Masters and PhD) Belfast Birmingham Bristol Cambridge Edinburgh Exeter Leeds London Manchester Oxford CENTRAL TEAM OFFICES Wellcome Trust Great Ormond Street DRIVE Unit RESEARCH LOCATIONS HDR UK Cambridge HDR UK London HDR UK Midlands HDR UK North HDR UK Oxford HDR UK Scotland HDR UK South-West HDR UK Wales and Northern Ireland

slide-9
SLIDE 9

With a growing community of researchers, innovators, technologists, clinicians, patients, & public across industry, NHS, academia and charities working together…

| 10

slide-10
SLIDE 10

Key senior leadership appointments made in February – December 2018 Founding partner of UK Health Data Research Alliance announced in December 2018 New Masters programmes announced June 2019 One Institute Strategy launched – April 2019 7 Hubs launched in September 2019 and started October 2019 Milestone 1 met by all Hubs December 2019 Industry engagement events UK, US, Europe October 2019 onwards Gateway MVP launch with >400 datasets February 2020 Alliance grows to 27 members January 2020

2018 2019 2020

Gateway Rapid Development Task January – March 2020

2017

HDR UK incorporated as a company limited by guarantee in July 2017 BHF and HDR UK start work in partnership to develop BHF Data Science Centre August 2018 Substantive Site call launched to form HDR UK’s research base in August 2017 Successful applicants announced forming our first six Substantive Sites in February 2018 Interim funding received and six Substantive Sites start in April 2018 First appointments made to the Board in November 2017 HDR UK chosen to lead development of 4-year Digital Innovation Hubs programme in July 2018 DIH Programme Design & dialogue September 2018 – April 2019 Core Funding starts and Call for National Implementation Projects launched August 2018 Further appointments made to the Board in November 2018 Collaboration with KQ Labs announced November 2018 UK Health Data Research Alliance launched with nine member in February 2019 11 Sprint Exemplars

  • perational

January 2019 – December 2019 DIH prospectus launched May 2019 First round of National Implementation Projects announced June 2019 Partnership with NICE announced July 2019 2018/19 Annual Review launched July 2019 Plans for Gateway MVP announced July 2019 Successful Wellcome PhD Programme announced in September 2019 HDR UK’s 100th Open Access

  • utput

published in September 2019 BHF Data Science Centre and inaugural Director announced in October 2019 Chair of International Advisory Board announced in October 2019 Gateway MVP developed October 2019 - January 2020 Call for new Substantive Sites and Better Care Catalysts launched in December 2019 HDR UK Public Advisory Board announced – January 2019 2020 /21 strategic delivery plan and governance structures announced in March 2020 HDR UK implements research question prioritisation process to support COVID-19 response in April 2020 New Substantive Sites and Better Care Catalysts announced in April 2020 First phase of fully functional Gateway delivered in June 2020 Andrew Morris announced as Director in March 2017

…to deliver at pace…

| 9

slide-11
SLIDE 11

…and make impact at scale Our highlights from the past year

| 12

slide-12
SLIDE 12

Working in Partnership to respond to COVID-19

slide-13
SLIDE 13

| 14

“Covid-19 — A Once-in-a- Century Pandemic?”

Bill Gates

New England Journal of Medicine, April 2020

slide-14
SLIDE 14

We are mobilising resources and championing the use of health data to respond to COVID-19

| 15

1 2 3

Co-ordinate and connect national data science driven research efforts related to COVID-19 Accelerate access to UK-wide priority data relevant to COVID-19 for research Leverage the best of the UK’s health data science capability to address the wider impact of the COVID- 19 pandemic, supporting vulnerable groups that will be hardest hit

Our three key priority areas are:

slide-15
SLIDE 15

We are operating a prioritisation process for health data research questions for SAGE – accelerating the ‘fittest’ questions…

| 16 Questions from researchers

106 health data research questions identified 36 prioritised for support and data access

slide-16
SLIDE 16

…and reporting new research insights transparently…

| 17

100 pre-print publications 86 active research studies in the national Trusted Research Environments

slide-17
SLIDE 17

…making it easier to discover and request access to COVID-19 relevant datasets via the Gateway

| 18

https://healthdatagateway.org/

slide-18
SLIDE 18

…ensuring the views of patients and public are heard and taken on board and we are transparent with our work

| 19

We are receiving input from the 62 members of our COVID-19 public advisory group, our Public Advisory Board and new lay members on our delivery groups.

  • Prioritising COVID-19 data research questions
  • Shaping our advise to SAGE
  • Advising on COVID-19 research projects – e.g.

the risk calculator ‘OurRisk.CoV’

  • Sharing questions and concerns on accelerated

data access

slide-19
SLIDE 19

Increasing our knowledge of this devastating disease and how to treat it

| 20

Examples

Data from the Symptom Study App identified loss

  • f sense of smell and taste as a recognised

symptom of COVID-19, influencing UK government policy Use of data has shown the impact of COVID-19 on vulnerable people with health conditions, including those with cancer and heart disease The RECOVERY trial has used data to establish there is no clinical benefit of hydroxychloroquine in hospitalised patients

slide-20
SLIDE 20

Scaling this up to a global response Launching today: International COVID-19 Data Research Alliance and Workbench

| 21

slide-21
SLIDE 21

| 22

Vision To unite data from international clinical trials, biomedical and health research to enable discoveries that benefit all people, everywhere, by reducing the harm of the COVID-19 pandemic. To build a trustworthy international partnership and enduring data infrastructure to support a rapid response to the current COVID-19 and future pandemics across the world. Mission

slide-22
SLIDE 22

Initial partners “start small, think big, move fast”

FUNDERS Bill and Melinda Gates Foundation Chan Zuckerberg Foundation Mastercard Minderoo Foundation Wellcome ALLIANCE PARTNERS African Academy of Sciences BREATHE Health Data Research Hub Generation Scotland Genomics England Global Alliance for Genomic Health HDR Network Canada Infectious Diseases Data Observatory (IDDO) TECHNICAL EXPERTISE Aridhia Mastercard Novartis Pharma SAIL SeRP (Secure eResearch Platform)

| 23

slide-23
SLIDE 23

| 24

Thank you for listening

For further information: enquiries@hdruk.ac.uk @HDR_UK www.hdruk.ac.uk

slide-24
SLIDE 24

International approaches to combatting the COVID-19 pandemic – how have data and technology been harnessed? Chairs:

  • Rhos Walker, Chief Science Strategy Officer, Health Data Research UK

Panellists:

  • Andreas Poensgen, Managing Partner, Turgot Venture
  • Effy Vayena, Chair of Bioethics, Swiss Institute of Technology
  • Teo Yik Ying, Dean of Saw Swee Hock School of Public Health, National

University of Singapore

Please use the Q&A function to ask questions to speakers. You are welcome to comment using the chat function, but we cannot guarantee this will be monitored.

slide-25
SLIDE 25

Responding to an international pandemic Germany’s response to COVID-19

  • Dr. Andreas Poensgen

Health Data Science in the COVID-19 Era: HDR UK ‘One Institute’ Conference June, 16th 2020

slide-26
SLIDE 26

The first wave and government interventions: overview

27

Source: Statista, RKI, Johns Hopkins, WHO, Handelsblatt

Real infection curve minus 5 to 12 days

It 2000 new cases

The story

19.1 - 27.2 Limited outbreak (Webasto / China) 27.2. New Cases : Skiing /Italy Citizen Level 4.3. Many businesses start home office City & Federal State level 10.3 No large events > 1000 11.3 Isolation for skiing tourist 16.3. State of emergency German national level 12.3 No large events > 1000 16.3 Closing of bars, restaurants, most shops

  • 19. 3

Merkel televised Speech 22.3. Lock down: 2 persons to meet, home 2.4. !!! Stopping flights from Iran etc.

#

Registered new cases p.d Germany Italy State of Emergency Public Policy Interventions Pro- longation

Steps to reopen

The probable peak Next Phase

slide-27
SLIDE 27

Insights

1. The success - not result of grand design & strategy or full readiness 2. Probably a combination

  • Outside chock: the „Italian tragedy“
  • Access to Asian experience (SK, T, S, Ch): clear what needed to be done
  • Early change of behaviour: physical distancing
  • Some federal states acting early
  • Angela Merkel & Robert Koch Institute

3. After the„Hammer“, society started to learn „dancing“, slowly, trial and error: How to…

  • interrupt transmissions opening up
  • test-trace-isolate
  • protect elderly and feeble
  • ramp up supplies & capacity
  • improve hospital treatment strategies

28

slide-28
SLIDE 28

The power of decentral decision-making & initiative Example: independent laboratories

29 20000 40000 60000 80000 100000 120000 140000 March 6 March 15 March 23 March 30 Early April

86 48 97 86 ~100

# of labs

Development a surprise for political decision makers

Many similar stories: e.g. ramp up of hospital capacity, getting masks, organizing test stations, etc..

> 600 % increase within a month

  • Independent laboratories
  • Direct relation with physicians
  • Adaptive to local needs
  • No government intervention

Testing capacity per day #

slide-29
SLIDE 29

Learning: You win on the local level

  • Understanding infection rates & dynamics
  • Learning physical distancing and appropriate behaviour
  • Testing, tracing, isolating
  • Protecting nursing homes etc.
  • Providing care / intensive care
  • Supply & procurement

30

Key success factors

  • Adaptation to local situation
  • Targeted local task forces in charge
  • Flexible availability of resources
  • Fast data availability & transparency
  • Operational effectiveness
  • Involving all shareholders
  • Communication

But support needed: central competence hubs & government:

  • Nat. & int. know how & best practice sharing, benchmarking, scientific insights, data infrastructure

Access to int. purchasing & procurement Financial resources, laws & regulation, law enforcement, corrective actions if the local level fails

slide-30
SLIDE 30

The role of science, data and technology: leverage focussed strategies

Principal approach to stay focussed

31

Monitor & Evaluate / Benchmark Implement Operate Share R&D Understand Innovate Develop Test

Key areas of activities to fight COVID 19

Monitor infection rates & dynamics Measures of physical distancing/ Behavioural change Test, trace, isolate Protecting elderly & feeble Providing care / intensive care Ensure supplies

Seek & use leverage Value chain per area

Real time data Social Media & Apps & UX Access to & analytics of data pools Open Source & Crowd Sourcing AI & decision support algorithms Insight / knowledge scouting & KM hubs Connectivity Studies / Research

slide-31
SLIDE 31

32

Thank you

  • Dr. Andreas Poensgen

Managing Partner Turgot Ventures AG ap@turgot.ch https://www.linkedin.com/in/andreas- poensgen-51903951/

slide-32
SLIDE 32

| |

  • Prof. Effy Vayena

Health Ethics and Policy Lab effy.vayena@hest.ethz.ch @EffyVayena

6/25/2020 33

COVID19 A perspective from Switzerland and the WHO

slide-33
SLIDE 33

| | 34

slide-34
SLIDE 34

| |

https://www.corona-data.ch/

35

slide-35
SLIDE 35

| |

agata.ferretti@hest.ethz.ch

36

slide-36
SLIDE 36

| |

▪ Science, policy and politics ▪ The Swiss science task force

▪ Subgroups ▪ Policy briefs ▪ Public engagement

6/2 5/2

agata.ferretti@hest.ethz.ch

37

slide-37
SLIDE 37

| | 6/2

5/2

agata.ferretti@hest.ethz.ch

38

Science- politics and the deus ex machina

YES

slide-38
SLIDE 38

WHO guidance

slide-39
SLIDE 39

| |

▪ 31 131 infections ▪ 1677 deaths ▪ New infections on June 15 - 14 ▪ “Extraordinary situation” to end on June 19th ▪ Contact tracing and testing ▪ App ▪ Cantonal responsibilities

40

At this point

slide-40
SLIDE 40

Turning Discovery into Healthier Communities

41 Turning Discovery into Healthier Communities

YY Teo Professor, Dean Saw Swee Hock School of Public Health

How will the world adapt to challenges from COVID-19: a case study of Singapore’s response

slide-41
SLIDE 41

42/49

slide-42
SLIDE 42

43/49

Situation in Singapore

slide-43
SLIDE 43

44/49

Situation in Singapore

Importations Community cases Total Migrant Workers in Dormitories

slide-44
SLIDE 44

45/49

Key Principle 1: Find, Trace, Test, Isolate

  • 50 teams of 10, 2 shifts, 7

days

  • 13,000 tests/day to 40,000

test/day in July

slide-45
SLIDE 45

46/49

Key Principle 2: Evidence-guided Policies

(Reducing contact transmission in both communities and schools at different times and for durations)

slide-46
SLIDE 46

47/49

Key Principle 2: Evidence-guided Policies

  • Commissioned by Chief Health Scientist to Public Health

Translational Unit in School of Public Health

  • Weekly synthesis of latest scientific and media reports on

key topics

  • http://sph.nus.edu.sg/covid-19/
slide-47
SLIDE 47

48/49

Key Principle 3: Clear Public Communications

slide-48
SLIDE 48

49/49

Border Control Measures

Border der Restri triction ctions

  • 24 Mar: Border closures to all short-

term visitors*

  • 9 Apr: All returning locals manda

dato tory ry 14 14-days s quarant antine ne in government- appointed hotels

  • Strict digital and in-person enforcement

cement meted penalties include fines, deportations and imprisonments * Not applicable to citizens, PRs and long- term pass holders (study, work)

  • “Fast lane” (air bridges) arrangements

with China for essent ntial ial busines ness s travel l

  • TBC: New Zealand, Australia, South

Korea, Malaysia

Temper peratur ture e Screening eening

  • 24 Jan: All land and sea checkpoints
  • 29 Jan: All flights into Singapore

Forf rfei eitur ure e of Health lth Insu surance ance

  • Locals who voluntari

tarily ly travel el for non- essent ential al purpose forfeit COVID-19 coverage

slide-49
SLIDE 49

50/49

COVID-19: Global Public Health

  • Commonalities in Public Health strategies, but important

context differences in implementation

  • Contextual elements:

▪ Historical (e.g. SARS, MERS, H1N1, etc.) ▪ Social and cultural (e.g. trust, community-spirited) ▪ Capacity and capability (testing, tracing, isolation, treatment) ▪ Economic (e.g. fiscal measures to protect livelihoods) ▪ Political (i.e. long-term outlook vs. short-term impact)

slide-50
SLIDE 50

51/49

Summary

  • Embarking on both

aggressive PCR and serology testing, and increased capability for contact tracing

  • Calibrated and phased easing of lockdown measures
  • Constant

risk assessments and possibly sectoral closures if resurgence

slide-51
SLIDE 51

Turning Discovery into Healthier Communities

52 Turning Discovery into Healthier Communities

Thank you!

ephtyy@nus.edu.sg

slide-52
SLIDE 52

International approaches to combatting the COVID-19 pandemic – how have data and technology been harnessed?

Chairs:

  • Rhos Walker, Chief Science Strategy Officer, Health Data Research UK

Panellists:

  • Andreas Poensgen, Managing Partner, Turgot Venture
  • Effy Vayena, Chair of Bioethics, Swiss Institute of Technology
  • Teo Yik Ying, Dean of Saw Swee Hock School of Public Health, National University of

Singapore

slide-53
SLIDE 53

Format & programme for the day

Rhos Walker, Chief Science Strategy Officer, Health Data Research UK

slide-54
SLIDE 54

Delegate pack:

slide-55
SLIDE 55

Programme for the day:

Stream 1 Stream 2 10:45 Breakout 1: How do we make the UK world leading for COVID-19 clinical trials? Breakout 2: COVID-19 Data – data definitions and new data types in a crisis 11:45 Breakout 3: Understanding the causes of disease & COVID 19 – Harnessing multi-omic cohorts & the COVID-19 Genomics UK Consortium Breakout 4: How are Health Data Research Hubs & BHF Data Science Centre supporting COVID-19 Research? PLENARY 12:45 Rapid Fire Early Career Lightning Talks 13:15 LUNCH BREAK Stream 1 Stream 2 13:50 Breakout 5: Better care – role of data at the frontline

  • f the COVID-19 response

Breakout 6: Responding to the Public Health Emergency

  • f COVID-19

14:50 Breakout 7: What do national and international health data researchers need in a post-COVID-19 world? Breakout 8: Relationship of trust: Realising patient and NHS benefits in times of COVID-19 PLENARY 15:50 Fireside chat: How will data and technology influence the future of clinical and regulatory science? 16:25 Celebrating partnership in health data science across the UK: Prize for ‘Impact of the Year’, ‘Team of the Year’ & Lightning Talks 16:35 Closing remarks 16:45 CLOSE

slide-56
SLIDE 56

Delegate pack:

slide-57
SLIDE 57

Accessing the sessions:

slide-58
SLIDE 58

Additional support:

  • If you have any problems accessing any sessions, please email events@hdruk.ac.uk and the team will

be able to help

  • Sessions will be recorded and where possible we will share the recordings and slides on our website

after the conference

  • We aim for the event will be as interactive as possible.
  • Please submit questions via the Q+A function. More details on how to submit questions are

included in your Delegate pack

  • Please tweet their thoughts and contributions using #HDRUKcon20
  • Enjoy the day!
slide-59
SLIDE 59

Break

The next session will start at 10:45BST.